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Objective. To assess the blood pressure control and cardiovascular risk factors (CVRFs) in a population of hypertensive patients
with access to care under a government-ﬁnanced program, the Cardiovascular Health Program (CHP). Design. A cross-sectional
and multicenter study. Setting. 52 primary care centers, metropolitan area of Santiago, Chile. Participants. 1,194 patients were
selected by a systematic random sampling from a universe of 316,654 hypertensive patients. Key Measurements. Demographic
information, blood pressure (BP) measurements, and CVRF were extracted from medical records of patients followed for a 12-
month period. Results. 59.7% of patients reached target BP < 140/90mmHg. More women were captured in the sampling (2.1:1),
achieving better BP control than men. Diabetic patients (26.4%) had worse BP control than nondiabetics. Antihypertensive
medications were used in 91.5%, with multidrug therapy more frequent in patients with higher BP and more diﬃcult control.
Conclusions.ThesuccessinimprovingtheBPcontroltovalues<140/90mmHgfrom45.3%to59.7%underscoresthecontribution
of this program in the Chilean primary care cardiovascular preventive strategies. However, fewer hypertensive men than women
were captured by this program, and it is of concern the underperforming of BP control observed in diabetics.
1.Introduction
Hypertension control has been instrumental to achieve a sig-
niﬁcant reduction in cardiovascular events. However, despite
the advancements in antihypertensive drug therapy, success
incontrollingBPtotheJoint NationalCommittee VIIguide-
lines (BP < 140/90mmHg) has been quite disappointing.
Most of the published information has reported satisfactory
BP control in only 30% to 45% of the hypertensive popula-
tion [1–5].
Numerous factors have been mentioned as responsible
for this limited results including socioeconomic status,
barriers in the access to health care, lack of a population-
orientedprogramfocusedonpreventivecardiovascularmea-
sures, poor adherence, among others [1, 6–8]. The Chilean
Ministry of Health started a Cardiovascular Health Pro-
gram (CHP) (Programa de Salud Cardiovascular, PSCV)
in 2002 with the objective of reducing the cardiovascular
morbidity and mortality by a global management strategy
of cardiovascular risk factors (CVRF) in patients followed
at the primary care level [9, 10]. Approximately 76.9% of
the Chilean population is enrolled in a primary care clinic
through the public health system. This is ﬁnanced by the
Ministry of Health through subsidies to the primary care2 International Journal of Hypertension
centers and clinics, some of them belonging to the private
sector [9]. Patients have access to the CHP once a diagnosis
of hypertension, diabetes, and/or dyslipidemia is established
after the initial primary care evaluation. By law every patient
enrolledinthepublichealthsystemiseligibleforapreventive
annual medical examination. Patients referred to the CHP
receive free followup and drug therapy at least every three
months through multidisciplinary teams composed by pri-
mary care physicians, nurses, dietitians, and social workers.
Patients are referred to a secondary health care system when
secondary hypertension is suspected or when they develop
complications such as ischemic heart disease, congestive
heart failure, cerebrovascular accident, and renal failure.
Currently, 1,485,862 patients are enrolled nationwide in the
CHP and near 400,000 patients in the metropolitan area of
Santiago.
The objectives of this study were twofold. First, to eval-
uate the proportion of CVRF in hypertensive patients, with
or without diabetes, followed under the CHP and, second,
to assess the eﬃcacy of this program in the blood pressure
control on this population.
2. Methods
2.1. Population Sample and Procedures. A multicenter cross-
sectional systematically randomized sample from a universe
of 316,654 hypertensive patients followed throughout the
CHP in 133 primary care centers was obtained from 52
municipalities of the metropolitan region of Santiago, Chile.
Patients who had BP readings ≥140/90mmHg throughout
their routine medical followups were referred to the CHP.
Primary care centers with >1,000 hypertensive patients
(97 from 133 centers) were randomly selected, one per
each of the 52 municipalities. A randomly selected sample
of 1,194 hypertensive patients representing proportionally
the total number of patients followed in each one of the
primary care centers selected was included in the study.
The sampling size (n = 1,194) was obtained with 95% of
conﬁdence,estimatederrorof5%,expectedprevalenceofBP
< 140/90mmHg of 50%, and design eﬀect of 3.0. Patients
were given follow-up appointments according to the clinical
assessment and a minimum of three visits per year after the
initial evaluation. Patients under 20 years of age, or suﬀering
signiﬁcant disabilities (bedridden, mentally incompetent,
wheel chair users), or with missing appointments (less than
three followup visits per year) were excluded (n = 23). After
replacing the exclusions according to a random procedure
using the EPI-Info software, each patient was randomly
selected in every one of the primary care centers included.
The data collection was completed in November 2006.
The medical records of 12 consecutive months of followup
were reviewed. Systolic and diastolic blood pressure (SBP
and DBP, resp.) measured by trained personnel throughout
3 successive controls at the corresponding CHP primary
care center according to international guidelines [5]a n d
using mercury sphygmomanometers was included for data
analysis. Occasional BP measurements performed outside
the CHP were not considered. Age, gender, weight, height,
education level (years of schooling), and smoking habit
(daily smokers) were recorded. Presence of diabetes was
established by clinical diagnosis and/or therapies prescribed.
All the antihypertensive medications were recorded. Choles-
terol levels (total and HDL) were obtained by standard
techniques and included for data analysis and only the last
ones recorded throughout the follow-up period.
All patients received lifestyle changes counseling (diet,
smoking cessation, physical activities) and antihypertensive
therapy freely prescribed and adjusted by the physician
during the follow-up visits in every primary care center.
2.2. Statistical Analysis. The demographic distribution by
gender and age of the 316,654 patients was used to calculate
the base weight for each sampling unit. Absolute expan-
sion sample weights were calculated using the respective
geographical distribution of each one of the primary care
centers included in the study allowing to minimize selection
bias. Internal and external validity was established by the
Z-binomial test comparing the sample (1,194) and the
universe (316,654). A multivariate logistical analysis was
performed to calculate the odds ratio (OR) 95% conﬁdence
intervals for the proportion of CVFR (high blood pressure,
total cholesterol, HDL cholesterol, body mass index (BMI),
smoking, education level) in hypertensive diabetic and non-
diabetic patients. In addition, the association between the
control of BP and diﬀerent factors was assessed in age- and
sex-adjusted logistic regression models.
3. Results
The age distribution showed no statistically signiﬁcant dif-
ferences between the universe and the sample. Mean age was
63.7 ± 1 3 . 6y e a r s ,w i t hn od i ﬀerences between men and
women (64.5 ± 13.1 versus 63.7 ± 13.6 years, P = 0.13)
(Table 1). A small proportion of patients with stable car-
diovascular comorbidities under routine specialized care
were observed in the sample: ischemic heart disease, 1.5%;
congestive heart failure, 3.8%; cerebrovascular accident,
3.2%; renal failure, 1.9%; arrhythmias, 1.6%.
More hypertensive women than men were captured by
the CHP (ratio 2.1:1). Table 2 includes the CVRF values
(%) in this population. Women had a higher proportion of
obesity than men (47.9% versus 33.1%, P<0.01) and HDL
< 50mg/dL in 51.8%; in contrast, men had HDL < 40mg/dL
in 33.2% (P<0.01). Men exhibited higher proportion of
smoking, overweight (BMI > 25–30kg/m2), and diabetes
than women (P<0.01). Table 3 compares the CVRF ex-
pressed as percentage found in this study with the results
reported by the 2010 Chilean National Health Survey [11]
in hypertensive and normal individuals.
The mean SBP was 135 ± 15mmHg, and it was higher
in men than in women (138 ± 16 versus 135 ± 15mmHg,
resp., P<0.01). The mean DBP was 81 ± 10mmHg, with
no statistically signiﬁcant diﬀerences by gender. It is of note
that 59.7% of the patients achieved a BP < 140/90mmHg,
although women had a larger proportion of controlled BP
than men (63.7% versus 52.4%, P<0.01).International Journal of Hypertension 3
Table 1: Age and gender distribution. Comparison of the weighted sample (n = 1,194) and the total hypertensive population (n = 316,654)
followed in the Cardiovascular Health Program (CHP), metropolitan area, Santiago, Chile.
Age
(years)
Men Women
Sample Hypertensive population
P-value
Sample Hypertensive population
P-value n % N % n % N %
20–34 7 1.9 2,102 2.2 0.68 18 2.3 4,793 2.2 0.91
35–44 22 5.7 6,186 6.3 0.61 64 7.7 18,875 8.7 0.29
45–54 63 16.4 14,546 14.9 0.41 147 18.1 41,567 19.2 0.31
55–64 85 22.4 24,465 25.0 0.24 203 25.0 54,626 25.3 0.93
65 or more 204 53.6 50,262 51.4 0.38 381 46.9 96,232 44.5 0.20
Total 381 100 97,561 100 813 100 216,093 100
Table 2: Percentage of cardiovascular risk factors by gender (weighted sample).
Men
n = 381
Women
n = 813
Total
n = 1,194
Average age (years) 63.7 ± 13.6 64.5 ± 13.1 63.3 ± 13.6
Percentage % (CI 95%)
Diabetes mellitus
(clinical diagnosis) 27.5 (27.2–27.8) 25.9 (25.7–26.1)∗ 26.4 (26.2–26.5)
Glycemia
≥100mg/dL 48.9 (48.5–49.1) 42.2 (41.9–42.4)∗ 44.3 (44.1–44.5)
Overweight
BMI > 25–29Kg/m2 47.1 (46.8–47.4) 35.5 (35.3–35.6)∗ 39.4 (36.6–42.2)
Obesity
BMI ≥ 30Kg/m2 33.1 (32.8–33.4) 47.9 (47.7–48.1)∗ 42.8 (42.2–43.4)
Total cholesterol
200–239mg/dL 36.6 (36.3–36.9) 34.8 (34.6–35.0)∗ 35.4 (35.2–35.5)
Total cholesterol
≥240mg/dL 16.1 (15.8–16.3) 26.1 (25.9–26.3)∗ 23.0 (22.8–23.1)
Cholesterol HDL
<40mg/dL 33.2 (32.8–33.5) — —
Cholesterol HDL
<50mg/dL — 51.8 (51.6–52.0)∗ —
Smoking 21.2 (20.9–21.5) 16.5 (16.3–16.7)∗ 18.0 (17.9–18.1)
Low education
<8 years 56.1 (55.8–56.5) 60.1 (59.8–60.4)∗ 58.8 (58.6–59.1)
∗P < 0.01 for comparison with men.
There were no statistically signiﬁcant age diﬀerences be-
tweendiabeticandnondiabetichypertensivepatients(64.0 ±
12.2 versus 62.9 ± 14.0 years; P = 0.18). Hypertensive
diabetic patients had worse BP control than nondiabet-
ics, achieving a BP < 140/90mmHg in 53.2% versus
62.4%, respectively (P<0.01), diﬀerence that persists al-
though attenuated when considering a level of control
<130/80mmHg (21.5% versus 24.9%, P<0.01) (Table 4,
Figure 1). Hypertensive diabetic patients also had a higher
proportion of obesity (BMI > 30kg/m2) and low HDL
(<40mg/dL) than nondiabetics (Table 4). After adjusting by
age and gender, diabetes and low education level were asso-
ciated with BP ≥ 140/90mmHg (OR 1.39 and 1.29, resp.,
Table 5) and, to a lesser extent, total cholesterol, low HDL
cholesterol, and BMI > 30kg/m2. Coexisting incidental car-
diovascular diseases were associated to BP < 140/90mmHg
(OR 0.77).
A large percentage of patients (91.5%) received antihy-
pertensive drug therapy (34.3% monotherapy and 57.1%
combination of drugs). Angiotensin-converting enzyme
inhibitors (ACEIs), diuretics, calcium channel, and β-block-
ers were the more frequently used drugs (Figure 2). Exclu-
sively nonpharmacological measures were used in 8.5% of
patients, and 75% of them achieved a BP < 140/90mmHg,
whereas only 57% of those under multidrug-therapy group
reached that goal. The relationship of BP control with the
type of therapy and the number of drugs used is shown
in Figure 3.A se x p e c t e d ,ag r e a t e ru s eo fac o m b i n a t i o n4 International Journal of Hypertension
Table 3: Proportion of cardiovascular risk factors in 1,194 hypertensive patients (CHP). Comparison with hypertensive and normotensive
individuals from the 2010 National Health Survey (NHS).
Hypertensive CHP
n = 1,194
Hypertensive NHS 2010
n = 1,101
Normotensive NHS 2010
n = 3,775
Average age (years) 63.3 ± 13.6 62.5 ± 13.9 40.1 ± 16.4
Percentage % (CI 95%)
Diabetes mellitus 26.4 (24.0–29.0) 17.5 (15.3–19.7)∗ 3.2 (2.6–3.7)†
Glycemia
(≥100 mg/dL) 44.3 (41.5–47.1) 55.7 (50.2–61.2)∗ 29.6 (28.1–31.1)†
Smoking 18.0 (15.8–20.2) 19.1 (16.8–21.4) 40.2 (38.6–41.8)†
Overweight
(BMI 25.0–29.9Kg/m2) 39.4 (36.6–42.1) 35.8 (32.9–38.6) 36.4 (34.9–37.9)
Obesity
(BMI ≥ 30Kg/m2) 42.8 (40.0–45.6) 44.4 (41.5–47.3)∗ 23.5 (22.1–24.9)†
Total cholesterol
(≥200mg/dL) 35.4 (32.5–38.2) 37.2 (34.3–40.1) 53.1 (51.5–54.7)†
Low education
< 8 years 58.8 (55.6–62.8) 27.9 (25.3–30.5)∗ 47.5 (45.9–49.0)†
∗P<0.01 for comparison with CHP sample, †P<0.01 for comparison with CHP sample.
Table 4: Cardiovascular risk factors: comparison between hypertensive diabetic and nondiabetic patients.
Risk factors Hypertensive nondiabetic
n = 882
Hypertensive diabetic
n = 312
OR (IC 95%)
n = 1,194
Average age (years) 62.9 ± 14.0 64.0 ± 12.2 —
Percentage % (CI 95%)
Blood pressure ≥ 140/90mmHg 38.0 (34.7–41.2) 46.8 (41.3–52.3)∗ 1.41 (1.08–1.84)
Blood pressure ≥ 130/80mmHg 75.1 (72.2–77.9) 78.5 (73.9–83.0)∗ 1.19 (0.87–1.62)
Total cholesterol 200–239mg/dL 36.5 (33.1–39.8) 32.6 (27.1–38.0)∗ 0.84 (0.63–1.12)
Total cholesterol ≥ 240mg/dL 23.9 (21.0–26.9) 20.7 (15.9–25.4)∗ 0.83 (0.60–1.17)
HDL cholesterol < 40 mg/dL 19.3 (16.5–22.0) 32.4 (26.6–37.5)∗ 2.03 (1.45–2.85)
Overweight (BMI 25.0– 29.0Kg/m2) 40.7 (37.5–43.9) 35.3 (30.0–40.6)∗ 0.78 (0.59–1.01)
Obesity (BMI ≥ 30Kg/m2) 39.5 (36.3–42.7) 51.9 (46.3–57.4)∗ 1.79 (1.37–2.38)
Low education (<8 years)† 39.3 (35.1–43.5) 44.5 (37.8–51.2)∗ 1.34 (1.32–1.38)
Smoking†† 18.3 (15.7–20.8) 16.1 (12.0–20.2)∗ 1.51 (1.47–1.55)
OR refers to odds ratio adjusted by age and gender; the reference group is hypertensive nondiabetic; †the category for nonresponse (38%) is included in
multivariate analyses; ††OR estimated for the category of daily smoker, including the category for nonresponse in multivariate analyses; ∗P<0.01 for
comparison with nondiabetic hypertensive patients.
62%
(a) Hypertensive nondiabetic (b) Hypertensive diabetic
22%
38 %
79 %
BP controlled
(< 140/90 mm Hg)
BP controlled
(< 130/80 mm Hg)
Figure 1: Proportion of satisfactory blood pressure (BP) control in the hypertensive population followed through the Cardiovascular Health
Program according to diabetic status.International Journal of Hypertension 5
Table 5: Association of diﬀerent factors with the control of blood pressure (BP) in a cohort of hypertensive patients, Cardiovascular Health
Program (CHP), Chile.
Risk factors BP < 140/90mmHg
n = 713
BP ≥ 140/90mmHg
n = 481
OR (IC95%)
n = 1,194
Average age (years) 61.9 ± 13.5 65.3 ± 13.4 —
Percentage % (CI 95%)
Diabetes mellitus 23.3 (20.2–26.4) 30.4 (26.3–34.5) 1.39 (1.37–1.41)
Total cholesterol 200–239mg/dL 30.4 (27.0–33.8) 34.1 (29.9–38.3) 1.18 (1.16–1.20)
Total cholesterol > 240mg/dL 20.9 (17.9–23.9) 20.6 (17.0–24.2) 1.02 (1.01–1.04)
HDL cholesterol < 40mg/dL 21.6 (18.6–24.6) 25.2 (21.3–29.1) 1.17 (1.15–1.20)
Overweight (BMI 25.0–29.0Kg/m2) 38.3 (34.7–41.9) 40.7 (36.3–45.1) 1.03 (1.01–1.04)
Obesity (BMI > 30Kg/m2) 42.4 (38.8–46.0) 43.2 (38.8–47.6) 1.17 (1.15–1.18)
Low education (<8 years)† 22.6 (19.5–25.7) 28.5 (24.5–32.5) 1.29 (1.27–1.38)
Smoking 19.6 (16.7–22.5) 14.8 (11.6–18.0) 0.97 (0.95–0.99)
Presence cardiovascular deiseasesΨ 8.9 (6.8–11.0) 8.3 (5.8–10.8) 0.77 (0.75–0.79)
OR refers to odds ratio adjusted by age and gender; the group of reference is BP < 140/90; †the category for nonresponse (38%) is included in multivariate
analyses; ∗P<0.01 for comparison with BP controlled, Ψpresence of stroke, heart failure, and ischemic heart disease.
of antihypertensive drugs (more often ACEI, angiotensin
receptor blockers (ARBs), β-blockersand diuretics) occurred
in hypertensive patients with BP more diﬃcult to control.
Some combinations appeared to be more eﬀective than oth-
ers (ACEI + diuretic and Calcium channel blocker + diuretic
versus β-blocker + diuretic and ARB + diuretic) (Figure 3).
There were no diﬀerences in the drug monotherapy utilized
in nondiabetic and diabetic hypertensive patients. ACEI plus
diuretics were more commonly used in nondiabetics, and
ARBs plus diuretics more often provided to diabetic patients
(Table 6).
4. Discussion
This study, which included a representative sample of the
hypertensive population followed through the Chilean Car-
diovascular Health Program (CHP) in the metropolitan
regionofSantiago(316,654patients),documentedaBPcon-
trol of <140/90mmHg in 59.7% of the patients and 91.5%
under antihypertensive drug therapy, comparable to the best
results obtained elsewhere [12]. In recent data released by
the Center of Disease Control in USA based in the National
Health and Nutrition Examination Survey (NHANES) only
69% of hypertensive patients were under antihypertensive
drug therapy and 46% had their BP < 140/90mmHg [5].
Furthermore, a signiﬁcant improvement was documented in
reference to previous Chilean National Health Surveys that
showed only 45.3% patients reaching that goal [11]. These
ﬁndings suggest that a primary care system with a program
aimingtodetecthypertensivepatientsandprovidethemwith
unrestricted access to medical monitoring and a compre-
hensive treatment program including lifestyle changes coun-
seling can be an eﬀective preventive strategy.
Nowadays, there is agreement that the simple access to
medical followup through provision of medical insurance
has not shown satisfactory BP control in hypertensive pa-
tients [2, 3, 5, 7]. Interestingly 8.5% of patients in our
primary care-based cohort were managed exclusively with
nonpharmacological measures, and 75% reached a target BP
< 140/90mmHg underscoring the importance of access to
ancillary services as dietary and lifestyle changes counseling
(e.g., increasing physical activity) along with the medical
followup. In contrast, drug combinations were used in more
than 50% of the subjects, achieving the desired goal of BP <
140/90mmHgonlyin57%andasexpected,lessfrequentlyin
patients with higher and more diﬃcult BP to control. These
results are probably reﬂecting diﬀerences in the severity
of hypertension, therapeutic adherence, or other unknown
factors in the population studied.
In regard to the factors identiﬁed to inﬂuence the control
of BP, after adjusting for age and gender in this Chilean
hypertensive cohort, diabetes and low education level were
associated to worse BP control—and, to a lesser extent,
obesity and blood lipids. The association between poor
control of BP and other CVRF is probably a reﬂection of
the diﬃculties for simultaneously controlling multiple risk
factors, especially in diabetic hypertensive patients. On the
other hand, in cross-sectional and prospective cohort studies
in diﬀerent countries—including Chilean adults—an inverse
association between education level and CVRF, cardiovas-
cular events and all-cause mortality has been consistently
established [13–21]. This study provides additional evidence
suggesting that low educational level seems to be a predictor
of poor control of BP in Chilean hypertensive patients.
Plausible explanations are related to the acquired skills and
knowledge for self-care, healthy lifestyles, and better adher-
ence to antihypertensive therapies with increasing education
levels[21].Thepresenceofcardiovascularcomplicationsalso
showed association with controlled BP, perhaps due to a dif-
ference in the lifestyle modiﬁcation counseling and a better
adherence to antihypertensive drug therapy after incidental
complications.
Several ﬁndings in this study represent a signiﬁcant
challenge for the CHP. First, the much larger proportion
of women than men (ratio 2.1:1) who entered the CHP is6 International Journal of Hypertension
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Figure 2: Antihypertensive drugs utilized in the Cardiovascular Health Program (CHP).
Monotherapy
Other combinations
0 17.5 35.0 52.5 70
Frequency (%)
66.3 %
60.4 %
59.1 %
51.8 %
50.0 %
48.0 %
ARBs + diuretics
B blockers + diuretics
ACEI + diuretics
CA++channel
blockers + diuretics
Figure 3: Antihypertensive drug therapy modalities used to achieve BP control (<140/90mmHg) in the Cardiovascular Health Program
(CHP).
not consistent with the Chilean prevalence of hypertension,
which is similar in both genders according to previous
National Health Surveys [11]. This fact indicates that the
program is not providing adequate coverage to the male
population.Probablylabor-relatedhurdlesinmenlimittheir
availability for routine medical followups in contrast to
women, most of them homemakers with more ﬂexible time
at their disposal. Second, the large proportion of hyperten-
sive diabetic patients with unsatisfactory BP control, 22%
reachingtherecommendedBP<130/80mmHg,underscores
the need to improve the BP management in this group. In
addition, they had a higher proportion of obesity and lower
HDL than nondiabetic hypertensive patients making them
particularly vulnerable to cardiovascular events. Finally,
this study shows that the presence of diabetes in this
hypertensive population is signiﬁcantly higher (26.4%) than
the prevalence (5.1%) in the general Chilean population
[11]. According to these results, over 100,000 patients treated
in the CHP present a comorbidity of hypertension and
diabetes in the metropolitan area. It is conceivable that a
better management of these patients at the primary care level
may have a signiﬁcant impact in reducing the morbidity,
mortality, and costs related to cardiovascular complications
in this highly vulnerable group of patients [22]. Others
have already reported this problem. A CVRF trends study
in nondiabetic and Type 2 diabetic patients followed for
35 years (1970–2005, Framingham Heart Study) showed
consistently higher BP in diabetics [23]. In Spain, a study
found that only 9.8% of the hypertensive diabetics had a BP
at the recommended target of <130/80mmHg. Some have
questionedwhethertheproposed levelofcontrolfordiabetic
hypertensive patients (BP < 130/80mmHg) is necessary or
achievablefromtheperspectiveofpublichealth[24,25].Our
experience in the CHP conﬁrms the diﬃculties in reaching
that goal.
Like the pioneering studies from the Framingham cohort
[26], a Chilean prospective cohort study (San Francisco
Project) has suggested that an adequate BP control may sig-
niﬁcantly reduce nonfatal cardiovascular events (myocardial
infarction, unstable angina, and cerebrovascular accidents)
inhypertensivepopulation,estimating80.3%reductionafter
5 years (population attributable risk) [16]. Considering this
estimate, the adequate BP control in 59.7% of patients could
achieve 47.9% reduction of cardiovascular complications
after 5 years of followup in the CHP. When compared
to the National Health Survey (45.3% achieving BP <
140/90mmHg), the CHP could predict an additional 11.5%
reduction in cardiovascular events in hypertensive popula-
tion.
There are several limitations in our study. One of them
is that we did not determine drug adherence, which will
be the subject of a future study. Poor adherence could have
been a factor to explain the worst BP control in diabetics.
Recently it has been suggested that in diabetics the buﬀeringInternational Journal of Hypertension 7
Table 6: Comparison of antihypertensive treatment modalities in hypertensive diabetic and nondiabetic patients.
Treatment modalities Hypertensive nondiabetic patients
n = 882 (%)
Hypertensive diabetic patients
n = 312 (%) P-value
Nonpharmacological 9.0 7.1 0.298
Pharmacological 91.0 92.9 0.298
Monotherapy 34.2 34.6 0.904
ACEI + diuretic 20.7 15.1 0.028
Calcium channel blockers + diuretic 6.8 6.1 0.663
β-blockers + diuretic 2.5 2.4 0.804
ARBs + diuretic 0.1 1.6 0.006
Other drugs combination 24.5 29.8 0.065
eﬀe c to fh yp e rt e n s i o no np a i ns e n s i t i vi typ r evi o u s l yr e p o rt e d
by several studies may be magniﬁed, leading to hyperalgesia
andthereforetoareluctanceofdiabetichypertensivepatients
to follow the antihypertensive treatment [27–30]. However,
one of the inclusion criteria for this study was that patients
regularly attended their medical appointments, which could
be an indirect suggestion that many of them adhered to the
recommended therapy. This requirement may also partially
explain the diﬀerences found with the results of the previous
National Health Survey based on general population [11].
In addition the number of men included in the study
compared to women was signiﬁcantly smaller, and this may
haveinﬂuencedsomeoftheresults.Nevertheless,becausethe
CHP is now a part of the primary care program in Chile,
the number of hypertensive patients to be followed in the
future is expected to increase along with the proportion of
men included.
It was of note that the frequency of smoking was lower in
this hypertensive population than the prevalence observed in
thegeneralpopulationoftheChileanNationalHealthSurvey
[11], diﬀerence that may be related to the lifestyle modiﬁca-
tion counseling as a part of the CHP. Other positive lifestyle
modiﬁcations in this population can include reduced salt
consumption and increased physical activity. These ﬁndings
along with the improvements in achieving a satisfactory BP
controlunderscorethesigniﬁcanceoftheCHPintheChilean
hypertensive population.
5. Conclusions
A Cardiovascular Health Program that provides unrestricted
access to comprehensive treatment and followup of hyper-
tensive patients seems to be an eﬀective strategy to address
a major cardiovascular preventive goal in a middle-income
developing country as Chile.
According to the results of this study and based on
p r o j e c t i o n sf r o mp r e v i o u ss t u d i e si ti se x p e c t e dt h a tb y
improving BP < 140/90mmHg to 59.7% as a consequence of
the CPH, 47.9% reduction of future nonfatal cardiovascular
events might occur in the hypertensive population of this
program. Remaining challenges are the need to improve the
underrepresentation of men and the management of hyper-
tensive diabetic patients.
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